SG11201600060VA - Orthogonal cas9 proteins for rna-guided gene regulation and editing - Google Patents

Orthogonal cas9 proteins for rna-guided gene regulation and editing

Info

Publication number
SG11201600060VA
SG11201600060VA SG11201600060VA SG11201600060VA SG11201600060VA SG 11201600060V A SG11201600060V A SG 11201600060VA SG 11201600060V A SG11201600060V A SG 11201600060VA SG 11201600060V A SG11201600060V A SG 11201600060VA SG 11201600060V A SG11201600060V A SG 11201600060VA
Authority
SG
Singapore
Prior art keywords
editing
rna
gene regulation
cas9 proteins
guided gene
Prior art date
Application number
SG11201600060VA
Other languages
English (en)
Inventor
George M Church
Kevin Esvelt
Prashant Mali
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of SG11201600060VA publication Critical patent/SG11201600060VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2999/00—Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00
    • C12N2999/007—Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11201600060VA 2013-07-10 2014-07-08 Orthogonal cas9 proteins for rna-guided gene regulation and editing SG11201600060VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361844844P 2013-07-10 2013-07-10
PCT/US2014/045700 WO2015006294A2 (en) 2013-07-10 2014-07-08 Orthogonal cas9 proteins for rna-guided gene regulation and editing

Publications (1)

Publication Number Publication Date
SG11201600060VA true SG11201600060VA (en) 2016-02-26

Family

ID=52280701

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201600060VA SG11201600060VA (en) 2013-07-10 2014-07-08 Orthogonal cas9 proteins for rna-guided gene regulation and editing
SG10201800213VA SG10201800213VA (en) 2013-07-10 2014-07-08 Orthogonal cas9 proteins for rna-guided gene regulation and editing
SG10201913015XA SG10201913015XA (en) 2013-07-10 2014-07-08 Orthogonal cas9 proteins for rna-guided gene regulation and editing

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201800213VA SG10201800213VA (en) 2013-07-10 2014-07-08 Orthogonal cas9 proteins for rna-guided gene regulation and editing
SG10201913015XA SG10201913015XA (en) 2013-07-10 2014-07-08 Orthogonal cas9 proteins for rna-guided gene regulation and editing

Country Status (12)

Country Link
US (4) US10329587B2 (enrdf_load_stackoverflow)
EP (2) EP3019204B1 (enrdf_load_stackoverflow)
JP (3) JP6718813B2 (enrdf_load_stackoverflow)
KR (2) KR102481330B1 (enrdf_load_stackoverflow)
CN (2) CN110819658B (enrdf_load_stackoverflow)
AU (4) AU2014287397B2 (enrdf_load_stackoverflow)
BR (1) BR112016000571B1 (enrdf_load_stackoverflow)
CA (2) CA2917639C (enrdf_load_stackoverflow)
IL (3) IL282489B (enrdf_load_stackoverflow)
RU (3) RU2748433C2 (enrdf_load_stackoverflow)
SG (3) SG11201600060VA (enrdf_load_stackoverflow)
WO (1) WO2015006294A2 (enrdf_load_stackoverflow)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2831144A1 (en) 2011-03-23 2012-09-27 Pioneer Hi-Bred International, Inc. Methods for producing a complex transgenic trait locus
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
RS57287B1 (sr) 2012-05-25 2018-08-31 Univ California Postupci i sastavi za rnk-usmerenu modifikaciju ciljane dnk i za rnk-usmerenu modulaciju transkripcije
LT3138910T (lt) 2012-12-06 2017-11-10 Sigma-Aldrich Co. Llc Crispr pagrįstas genomo modifikavimas ir reguliavimas
DK3553174T3 (da) * 2012-12-17 2025-08-04 Harvard College Rna-guided modificering af humant genom
AU2014253942B9 (en) 2013-04-16 2020-08-13 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
ES2729635T3 (es) 2013-08-22 2019-11-05 Pioneer Hi Bred Int Modificación genómica usando sistemas de polinucleótido guía/endonucleasa Cas y métodos de uso
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US20150079680A1 (en) 2013-09-18 2015-03-19 Kymab Limited Methods, cells & organisms
US11326209B2 (en) * 2013-11-07 2022-05-10 Massachusetts Institute Of Technology Cell-based genomic recorded accumulative memory
DK3066201T3 (en) 2013-11-07 2018-06-06 Editas Medicine Inc CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES
US9546384B2 (en) 2013-12-11 2017-01-17 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse genome
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
US11028388B2 (en) 2014-03-05 2021-06-08 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
EP3553176A1 (en) 2014-03-10 2019-10-16 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
EP3981876A1 (en) 2014-03-26 2022-04-13 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3628739B1 (en) 2014-09-12 2024-05-01 Corteva Agriscience LLC Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
WO2016057961A1 (en) 2014-10-10 2016-04-14 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
GB201418965D0 (enrdf_load_stackoverflow) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
EP4464338A3 (en) 2014-11-07 2025-02-12 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
JP7068821B2 (ja) 2014-12-03 2022-05-17 アジレント・テクノロジーズ・インク 化学修飾を有するガイドｒｎａ
CN107249318A (zh) 2014-12-10 2017-10-13 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
WO2016160389A1 (en) 2015-03-27 2016-10-06 E I Du Pont De Nemours And Company Soybean u6 small nuclear rna gene promoters and their use in constitutive expression of small rna genes in plants
JP6873911B2 (ja) 2015-04-06 2021-05-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 初代細胞において標的核酸の遺伝子調節を誘導するためにインビトロで行う方法
CN107690480B (zh) 2015-04-24 2022-03-22 爱迪塔斯医药公司 Cas9分子/指导rna分子复合物的评价
WO2016182959A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
US20190136248A1 (en) * 2015-05-15 2019-05-09 Pioneer Hi-Bred International, Inc. Novel guide rna/cas endonuclease systems
US11298410B2 (en) 2015-06-01 2022-04-12 Temple University—Of the Commonwealth System of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
JP7396783B2 (ja) 2015-06-09 2023-12-12 エディタス・メディシン、インコーポレイテッド 移植を改善するためのｃｒｉｓｐｒ／ｃａｓ関連方法および組成物
WO2016205745A2 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
IL295616A (en) 2015-07-31 2022-10-01 Us Health Adapted cells and treatment methods
AU2016326711B2 (en) 2015-09-24 2022-11-03 Editas Medicine, Inc. Use of exonucleases to improve CRISPR/Cas-mediated genome editing
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and uses thereof
WO2017074943A1 (en) * 2015-10-27 2017-05-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of inducibly targeting chromatin effectors and compositions for use in the same
ES2930643T3 (es) 2015-11-23 2022-12-20 Univ California Seguimiento y manipulación de ARN celular a través de la administración nuclear de CRISPR/CAS9
BR112018013663A2 (pt) 2016-01-11 2019-01-22 Univ Leland Stanford Junior proteínas quiméricas e métodos de imunoterapia
IL304088A (en) 2016-01-11 2023-08-01 Univ Leland Stanford Junior Systems containing chimeric proteins and their uses for controlling gene expression
US11254928B2 (en) 2016-01-15 2022-02-22 Astrazeneca Ab Gene modification assays
WO2017165862A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP4495248A3 (en) * 2016-04-12 2025-04-02 CarryGenes Bioengineering, LLC Methods for creating synthetic chromosomes having gene regulatory systems and uses thereof
JP7497139B2 (ja) 2016-04-12 2024-06-10 キャリージーンズ バイオエンジニアリング 生合成経路を発現する合成染色体の作成方法及びその使用
EP3443086B1 (en) 2016-04-13 2021-11-24 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
US11779657B2 (en) 2016-06-10 2023-10-10 City Of Hope Compositions and methods for mitochondrial genome editing
BR112019001887A2 (pt) 2016-08-02 2019-07-09 Editas Medicine Inc composições e métodos para o tratamento de doença associada a cep290
IL264565B2 (en) 2016-08-03 2024-07-01 Harvard College Adenosine nuclear base editors and their uses
JP7201153B2 (ja) 2016-08-09 2023-01-10 プレジデント アンド フェローズ オブ ハーバード カレッジ プログラム可能ｃａｓ９－リコンビナーゼ融合タンパク質およびその使用
CN106282228A (zh) * 2016-08-19 2017-01-04 苏州兰希亚生物科技有限公司 一种基因点突变修复的方法
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US20190225974A1 (en) 2016-09-23 2019-07-25 BASF Agricultural Solutions Seed US LLC Targeted genome optimization in plants
WO2018071868A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
CA3041068A1 (en) 2016-10-18 2018-04-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
WO2018083606A1 (en) 2016-11-01 2018-05-11 Novartis Ag Methods and compositions for enhancing gene editing
EP3555297A1 (en) 2016-12-19 2019-10-23 Editas Medicine, Inc. Assessing nuclease cleavage
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
JP7229923B2 (ja) 2017-01-06 2023-02-28 エディタス・メディシン、インコーポレイテッド ヌクレアーゼ切断を評価する方法
AU2018212986B2 (en) * 2017-01-28 2024-07-25 Inari Agriculture Technology, Inc. Novel plant cells, plants, and seeds
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
WO2018148647A2 (en) * 2017-02-10 2018-08-16 Lajoie Marc Joseph Genome editing reagents and their use
WO2018156818A1 (en) * 2017-02-22 2018-08-30 Io Biosciences, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
US10828330B2 (en) 2017-02-22 2020-11-10 IO Bioscience, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
EP3596217A1 (en) 2017-03-14 2020-01-22 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
WO2018170015A1 (en) * 2017-03-14 2018-09-20 The Regents Of The University Of California Engineering crispr cas9 immune stealth
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
AU2017407272B2 (en) 2017-03-30 2024-06-13 Kyoto University Method for inducing exon skipping by genome editing
CN116555353A (zh) 2017-04-20 2023-08-08 E开创生物技术股份有限公司 产生基因修改的动物的方法
WO2018201086A1 (en) 2017-04-28 2018-11-01 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
EP3622062A4 (en) 2017-05-10 2020-10-14 The Regents of the University of California DIRECTED EDITING OF CELLULAR RNA BY NUCLEAR ADMINISTRATION OF CRISPR / CAS9
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
CN110997908A (zh) 2017-06-09 2020-04-10 爱迪塔斯医药公司 工程化的cas9核酸酶
WO2019003193A1 (en) 2017-06-30 2019-01-03 Novartis Ag METHODS FOR TREATING DISEASES USING GENE EDITING SYSTEMS
CN111511375A (zh) 2017-06-30 2020-08-07 因提玛生物科学公司 用于基因治疗的腺相关病毒载体
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
AU2018338318B2 (en) * 2017-09-21 2022-12-22 Massachusetts Institute Of Technology Systems, methods, and compositions for targeted nucleic acid editing
US11603536B2 (en) 2017-09-29 2023-03-14 Inari Agriculture Technology, Inc. Methods for efficient maize genome editing
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
WO2019089803A1 (en) 2017-10-31 2019-05-09 The Broad Institute, Inc. Methods and compositions for studying cell evolution
WO2019087113A1 (en) 2017-11-01 2019-05-09 Novartis Ag Synthetic rnas and methods of use
WO2019094791A2 (en) * 2017-11-10 2019-05-16 University Of Massachusetts Targeted crispr delivery platforms
MX2020007466A (es) 2018-01-12 2020-11-12 Basf Se Gen subyacente al qtl de la cantidad de espiguillas por espiga en trigo en el cromosoma 7a.
CN112020554B (zh) 2018-02-23 2024-10-22 先锋国际良种公司 新颖cas9直系同源物
MX2020009487A (es) 2018-03-14 2020-12-10 Editas Medicine Inc Sistemas y metodos para el tratamiento de hemoglobinopatias.
CA3089331A1 (en) 2018-03-19 2019-09-26 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
JP6614622B2 (ja) * 2018-04-17 2019-12-04 国立大学法人名古屋大学 植物ゲノム編集方法
CA3096713A1 (en) 2018-04-19 2019-10-24 The Regents Of The University Of California Compositions and methods for gene editing
EP3797160A1 (en) 2018-05-23 2021-03-31 The Broad Institute Inc. Base editors and uses thereof
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC GUIDANCE MOLECULES, COMPOSITIONS AND METHODS RELATED
GB201813011D0 (en) 2018-08-10 2018-09-26 Vib Vzw Means and methods for drought tolerance in crops
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US10934536B2 (en) 2018-12-14 2021-03-02 Pioneer Hi-Bred International, Inc. CRISPR-CAS systems for genome editing
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3696189A1 (en) * 2019-02-14 2020-08-19 European Molecular Biology Laboratory Means and methods for preparing engineered target proteins by genetic code expansion in a target protein selective manner
WO2020191248A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Method and compositions for editing nucleotide sequences
AU2020357816A1 (en) * 2019-09-30 2022-04-14 Sigma-Aldrich Co. Llc Modulation of microbiota compositions using targeted nucleases
US20230203463A1 (en) * 2019-12-30 2023-06-29 LifeEDIT Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
JP7525140B2 (ja) * 2020-01-31 2024-07-30 国立大学法人京都大学 タンパク質翻訳の制御システム
KR20230019843A (ko) 2020-05-08 2023-02-09 더 브로드 인스티튜트, 인코퍼레이티드 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물
GB202007943D0 (en) * 2020-05-27 2020-07-08 Snipr Biome Aps Products & methods
RU2749307C1 (ru) * 2020-10-30 2021-06-08 Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт сельскохозяйственной биотехнологии" (ФГБНУ ВНИИСБ) Новая компактная нуклеаза CAS9 II типа из Anoxybacillus flavithermus
WO2022116139A1 (zh) * 2020-12-04 2022-06-09 中国科学院脑科学与智能技术卓越创新中心 一种检测细胞内源性低丰度基因和lncRNA水平的方法
CA3207527A1 (en) 2021-02-05 2022-08-11 Eric B. Kmiec Methods of and compositions for reducing gene expression and/or activity
AU2022343300A1 (en) 2021-09-10 2024-04-18 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
IL312452A (en) 2021-11-01 2024-06-01 Tome Biosciences Inc A transformant has a single structure for the simultaneous transfer of a gene editing mechanism and a nucleic acid cargo
AU2022420615A1 (en) 2021-12-22 2024-07-04 Tome Biosciences, Inc. Co-delivery of a gene editor construct and a donor template
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
WO2024138194A1 (en) 2022-12-22 2024-06-27 Tome Biosciences, Inc. Platforms, compositions, and methods for in vivo programmable gene insertion
WO2024234006A1 (en) 2023-05-11 2024-11-14 Tome Biosciences, Inc. Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
WO2025050069A1 (en) 2023-09-01 2025-03-06 Tome Biosciences, Inc. Programmable gene insertion using engineered integration enzymes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933378B2 (en) * 1997-05-30 2005-08-23 Joseph Atabekov Methods for coexpression of more than one gene in eukaryotic cells
US6203986B1 (en) 1998-10-22 2001-03-20 Robert H. Singer Visualization of RNA in living cells
RU2467069C2 (ru) * 2006-03-09 2012-11-20 Зе Скрипс Ресеч Инститьют Система экспрессии компонентов ортогональной трансляции в эубактериальной клетке-хозяине
EP2518155B1 (en) * 2006-08-04 2014-07-23 Georgia State University Research Foundation, Inc. Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity
SI2126130T1 (sl) 2007-03-02 2015-10-30 Dupont Nutrition Biosciences Aps Kulture z izboljšano fagno odpornostjo
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US20100076057A1 (en) * 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
US10087431B2 (en) 2010-03-10 2018-10-02 The Regents Of The University Of California Methods of generating nucleic acid fragments
AU2011253222B2 (en) 2010-05-10 2014-08-21 The Regents Of The University Of California Endoribonuclease compositions and methods of use thereof
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
US20140113376A1 (en) 2011-06-01 2014-04-24 Rotem Sorek Compositions and methods for downregulating prokaryotic genes
WO2013066438A2 (en) * 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
SG10201606959PA (en) 2012-02-24 2016-09-29 Hutchinson Fred Cancer Res Compositions and methods for the treatment of hemoglobinopathies
NZ629427A (en) 2012-02-29 2016-04-29 Sangamo Biosciences Inc Methods and compositions for treating huntington’s disease
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
RS57287B1 (sr) 2012-05-25 2018-08-31 Univ California Postupci i sastavi za rnk-usmerenu modifikaciju ciljane dnk i za rnk-usmerenu modulaciju transkripcije
HK1207111A1 (en) 2012-08-03 2016-01-22 加利福尼亚大学董事会 Methods and compositions for controlling gene expression by rna processing
LT3138910T (lt) * 2012-12-06 2017-11-10 Sigma-Aldrich Co. Llc Crispr pagrįstas genomo modifikavimas ir reguliavimas
AU2013359212B2 (en) 2012-12-12 2017-01-19 Massachusetts Institute Of Technology Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
SG10201912328UA (en) * 2012-12-12 2020-02-27 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
DK3553174T3 (da) * 2012-12-17 2025-08-04 Harvard College Rna-guided modificering af humant genom
EP4389903A3 (en) * 2013-06-05 2024-10-16 Duke University Rna-guided gene editing and gene regulation

Also Published As

Publication number Publication date
AU2020200163B2 (en) 2021-08-26
IL282489A (en) 2021-06-30
US20150259684A1 (en) 2015-09-17
CA3218040A1 (en) 2015-01-15
AU2021273624C1 (en) 2025-02-06
CN110819658B (zh) 2024-03-22
CN105517579B (zh) 2019-11-15
AU2020200163A1 (en) 2020-01-30
EP3666892A1 (en) 2020-06-17
NZ716605A (en) 2021-05-28
CA2917639C (en) 2024-01-02
IL243476A0 (en) 2016-03-31
CN110819658A (zh) 2020-02-21
RU2704981C2 (ru) 2019-11-01
AU2021273624A1 (en) 2021-12-16
RU2019132195A3 (enrdf_load_stackoverflow) 2020-05-29
US20190367948A1 (en) 2019-12-05
SG10201800213VA (en) 2018-02-27
KR102481330B1 (ko) 2022-12-23
RU2016104161A (ru) 2017-08-15
US9587252B2 (en) 2017-03-07
US10329587B2 (en) 2019-06-25
US20230257781A1 (en) 2023-08-17
RU2748433C2 (ru) 2021-05-25
US11649469B2 (en) 2023-05-16
IL270259B (en) 2021-05-31
KR20210098547A (ko) 2021-08-10
NZ754837A (en) 2021-08-27
EP3019204A4 (en) 2017-04-05
HK1217907A1 (en) 2017-01-27
AU2014287397A1 (en) 2016-02-04
WO2015006294A2 (en) 2015-01-15
RU2019132195A (ru) 2019-11-28
WO2015006294A3 (en) 2015-11-26
NZ754836A (en) 2021-08-27
RU2771583C1 (ru) 2022-05-06
JP2016523560A (ja) 2016-08-12
EP3019204A2 (en) 2016-05-18
RU2016104161A3 (enrdf_load_stackoverflow) 2018-03-12
IL243476B (en) 2019-11-28
AU2014287397B2 (en) 2019-10-10
CA2917639A1 (en) 2015-01-15
JP7153992B2 (ja) 2022-10-17
US20160222416A1 (en) 2016-08-04
AU2020200163C1 (en) 2021-12-16
JP6718813B2 (ja) 2020-07-08
KR20160027191A (ko) 2016-03-09
JP2020072707A (ja) 2020-05-14
SG10201913015XA (en) 2020-02-27
CN105517579A (zh) 2016-04-20
KR102285485B1 (ko) 2021-08-04
AU2024227690A1 (en) 2024-11-21
JP2022176275A (ja) 2022-11-25
EP3019204B1 (en) 2020-01-01
BR112016000571A2 (enrdf_load_stackoverflow) 2017-07-25
BR112016000571B1 (pt) 2023-12-26
IL282489B (en) 2022-07-01
AU2021273624B2 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
IL282489A (en) cas9 proteins orthogonal to the regulation and editing of guided genes - RNA" A
EP3004370A4 (en) Rna-guided gene editing and gene regulation
IL284773B1 (en) RNA-guided transcriptional regulation
EP3452055A4 (en) IMPROVED METHODS OF GENOME EDITING WITH AND WITHOUT PROGRAMMABLE NUCLEASES
EP3071694A4 (en) Mutant cas9 proteins
IL248389A0 (en) A variable geometry fan
SG10201710218RA (en) Sc-beta cells and compositions and methods for generating the same
EP3255770A4 (en) Filter and power supply system
EP2972628A4 (en) MODULAR DRONE AND CORRESPONDING METHODS OF USE
GB2528395B (en) Apparatus and methods for geosteering
GB2535084B (en) Method and system for magnetic ranging and geosteering
IL257170A (en) Stable proteins and methods for their design
WO2017107898A9 (en) Compositions and methods for gene editing
EP3149789A4 (en) Connector for battery and battery comprising the same
SI3087989T1 (sl) Trdni pripravki, ki vsebujejo tofogliflozin in postopek njihove izdelave
GB2585807B (en) Ventilation ducts and connectors therefor
GB2545446B (en) Power distribution connector
EP3247000A4 (en) Charging connector and trolley having same
HK40113567A (en) Rna-guided gene editing and gene regulation
EP2892342A4 (en) ANTIBIOFILM AND PROCESS FOR ITS MANUFACTURE AND USE
HK40116839A (en) Evolved cas9 proteins for gene editing
HUP1500597A1 (hu) Kombinált légáramú mágneses és elektromos (KLME) szeparátor
HK1260084A1 (en) Methods and compositions utilizing cpf1 for rna-guided gene editing
SI3041820T1 (sl) (S,S)-EDDS biosintezni geni in proteini ter postopek za biosintezo (S,S)-EDDS
PH32015000086S1 (en) Rechargeable desk fan